Business
The Moderna way to profit from CSL’s vaccine challengers – The Australian Financial Review
Why the technology behind Moderna’s vaccine stands to disrupt CSL and how the spectacular collapse of Theranos exemplifies the need for biotech investors to always…
Ogden says that while sceptics of Moderna have targeted its lack of experience and unproven technology, the growing evidence of progress supports the view that it will be able to execute on the mammoth task of validation and distribution.
And the market agrees. The Nasdaq-listed company’s shares have surged more than sixfold over the last 12 months, closing at $US127.03 at the end of last week after telling investors it had signed a deal with the European Union to supply up to 160 million doses…
-
General23 hours agoEnglish springer spaniels Kelly and Milo helping fight dieback in Western Australia
-
Noosa News20 hours agoMega-team of heavy horses sets world record at Good Old Days Festival
-
Noosa News12 hours agoNRL grand final quick hits: Reece Walsh creates magic after avoiding sin bin as Broncos survive Hunt, Reynolds injuries to win premiership
-
General12 hours agoHow the internet reacted to Brisbane Broncos winning the NRL grand final